SSc patients n=50	(25% - 75% percentile)
Median age (years)	62 (56-71)
Median disease duration in years	13 (10-20)
Male / female	06/44
Clinical Features	n (%)
Diffuse cutaneous form *	23 (46)
Ulcers, scars, gangrene	21 (42)
Pulmonary fibrosis **	20 (40)
Pulmonary arterial hypertension (PAH) ***	7 (14)
Digestive involvement	39 (78)
Kidney involvement	5 (10)
Immunological Results	n (%)
Positive for anti-nuclear antibodies	50 (100)
- centromeric staining (ACA)	18 (36)
- homogeneous nucleoplasmic and nucleolar staining	15 (30)
- nucleolar staining	7 (14)
- homogeneous and speckled nucleoplasmic staining	8 (16)
- speckled nucleoplasmic staining	2 (4)
- positive for anti-topoisomerase I (anti-topo I)	25 (50)

## TABLE E1. Demographic data and disease characteristics of SSc patients.

n: number of subjects

\* According to the classification of LeRoy et *al.*<sup>6</sup>

\*\* Pulmonary fibrosis was defined on HRCT imaging (when available) and pulmonary function tests.

\*\*\* Pulmonary arterial hypertension was detected by echocardiography and confirmed by right heart catheterism if necessary.